Business Context and Reporting Period
This Form 6-K filing by Novo Nordisk A/S, dated February 9, 2026, reports on the initiation of a new share repurchase programme. Novo Nordisk is a leading global healthcare company headquartered in Denmark, employing approximately 68,800 people across 80 countries. The filing details corporate actions taken between February 4 and February 6, 2026.
Key Financial Metrics and Capital Actions
The filing focuses on capital allocation rather than operational financial performance. Key metrics regarding the share repurchase programme include:
- Total Programme Size: Up to DKK 15 billion to be executed over a 12-month period starting February 4, 2026.
- Initial Tranche: Up to DKK 3.8 billion for the period from February 4, 2026, to May 4, 2026.
- Transactions to Date (Feb 4–6, 2026): 750,000 B shares repurchased.
- Average Purchase Price: DKK 296.40 per B share.
- Total Transaction Value: DKK 222,297,903.
- Treasury Shares: Total holdings stand at 18,283,326 B shares (0.4% of share capital).
- Total Share Capital: 4,465,000,000 A and B shares (including treasury shares).
The filing text does not provide values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
The primary material change is the commencement of the new DKK 15 billion share buyback programme. Additionally, there was a net transfer of 3,841,954 B shares from the company related to incentive programmes during the same period; these transactions were distinct from the Safe Harbour repurchase programme.
Guidance, Outlook, and Risks
Management has outlined an expectation to repurchase B shares totaling up to DKK 15 billion over the next 12 months. The company continues to pursue its purpose of defeating serious chronic diseases, with a heritage in diabetes. The filing does not contain specific financial guidance, risk factors, or contingencies beyond the standard execution of the repurchase programme under EU Market Abuse Regulation (MAR) Safe Harbour Rules.
Investor Verification Checklist
- Verify the remaining capacity of the DKK 15 billion programme after the initial DKK 222 million execution.
- Confirm the impact of the 3.8 million shares transferred for incentive programmes on the total share count.
- Monitor future transaction details published on novonordisk.com for ongoing buyback activity.
- Review the company's Form 20-F for comprehensive financial statements, as this 6-K does not contain revenue or earnings data.